Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394245 | 0.76 | PKM (0.49) | MAPTKDM4EHPGDPOLBGAA | |
| SCHEMBL7239242 | 0.75 | SMN1; SMN2 (0.42) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL18701235 | 0.75 | KDM4E (0.41) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL18061139 | 0.74 | PTPN1 (0.48) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL7242405 | 0.74 | SMN1; SMN2 (0.39) | MAPTKDM4EHPGDHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7242414 | 0.74 | SMN1; SMN2 (0.42) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL28686949 | 0.73 | EGFR (0.47) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL18701129 | 0.72 | MAPT (0.41) | MAPTKDM4EHPGDGAAHSD17B10 | |
| SCHEMBL13424034 | 0.72 | CNR2 (0.43) | MAPTKDM4EHPGDPOLBGAA | |
| SCHEMBL3593308 | 0.70 | MEN1 (0.34) | MAPTPOLBNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691842-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1499622-B1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | WYETH CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1885358-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007030166-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D β-LACTAMASES INHIBITORS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1499622-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
| WO-2003093280-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS ΒΕΤΑ-LACTAMASE INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | MAPT 3052/4885KDM4E 1977/4885HPGD 728/4885 |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | MAPT 2034/4885KDM4E 1243/4885HPGD 563/4885 |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, MGAM, PREP | MAPT 2034/4885KDM4E 1243/4885HPGD 563/4885 |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, PGLS, MGAM | MAPT 3913/4885KDM4E 651/4885HPGD 397/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | MAPT 2074/4885KDM4E 1360/4885HPGD 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.